Supervised machine learning models applied to disease diagnosis and prognosis

Prediction of adolescent depression from prenatal and childhood data from ALSPAC using machine learning

Depression is a major cause of disability and mortality for young people worldwide and is typically first diagnosed during adolescence. In this work, we present a machine learning framework to predict adolescent depression occurring between ages 12 and 18 years using environmental, biological, and lifestyle features of the child, mother, and partner from the child's prenatal period to age 10 years using data from 8467 participants enrolled in the Avon Longitudinal Study of Parents and Children (ALSPAC). We trained and compared several cross-sectional and longitudinal machine learning techniques and found the resulting models predicted adolescent depression with recall (0.59 ± 0.20), specificity (0.61 ± 0.17), and accuracy (0.64 ± 0.13), using on average 39 out of the 885 total features (4.4%) included in the models. The leading informative features in our predictive models of adolescent depression were female sex, parental depression and anxiety, and exposure to stressful events or environments. This work demonstrates how using a broad array of evidence-driven predictors from early in life can inform the development of preventative decision support tools to assist in the early detection of risk for mental illness.

Developing the breast cancer risk prediction system using hybrid machine learning algorithms

BACKGROUND

Breast cancer (BC) is the most common cause of cancer-related deaths in women globally. Currently, many machine learning (ML)-based predictive models have been established to assist clinicians in decision making for the prediction of BC. However, preventing risk factor formation even with having healthy lifestyle behaviors or preventing disease at early stages can significantly lead to optimal population-wide BC health. Thus, we aimed to develop a prediction model by using a genetic algorithm (GA) incorporating several ML algorithms for the prediction and early warning of BC.

MATERIAL AND METHODS

The data of 3168 healthy individuals and 1742 patient case records in the BC Registry Database in Ayatollah Taleghani hospital, Abadan, Iran were analyzed. First, a modified hybrid GA was used to perform feature selection and optimization of selected features. Then, with the use of selected features, several ML algorithms were trained to predict BC. Afterward, the performance of each model was measured in terms of accuracy, precision, sensitivity, specificity, and receiver operating characteristic (ROC) curve metrics. Finally, a clinical decision support system based on the best model was developed.

RESULTS

After performing feature selection, age, consumption of dairy products, BC family history, breast biopsy, chest X-ray, hormone therapy, alcohol consumption, being overweight, having children, and education statuses were selected as the most important features for prediction of BC. The experimental results showed that the decision tree yielded a superior performance than other ML models, with values of 99.3%, 99.5%, 98.26% for accuracy, specificity, and sensitivity, respectively.

CONCLUSION

The developed predictive system can accurately identify persons who are at elevated risk for BC and can be used as an essential clinical screening tool for the early prevention of BC and serve as an important tool for developing preventive health strategies.

OMICS in Chronic Kidney Disease: Focus on Prognosis and Prediction

Chronic kidney disease (CKD) patients are characterized by a high residual risk for cardiovascular (CV) events and CKD progression. This has prompted the implementation of new prognostic and predictive biomarkers with the aim of mitigating this risk. The ‘omics’ techniques, namely genomics, proteomics, metabolomics, and transcriptomics, are excellent candidates to provide a better understanding of pathophysiologic mechanisms of disease in CKD, to improve risk stratification of patients with respect to future cardiovascular events, and to identify CKD patients who are likely to respond to a treatment. Following such a strategy, a reliable risk of future events for a particular patient may be calculated and consequently the patient would also benefit from the best available treatment based on their risk profile. Moreover, a further step forward can be represented by the aggregation of multiple omics information by combining different techniques and/or different biological samples. This has already been shown to yield additional information by revealing with more accuracy the exact individual pathway of disease.

Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington's Disease

Huntington's disease (HD) is characterised by a triad of cognitive, behavioural, and motor symptoms which lead to functional decline and loss of independence. With potential disease-modifying therapies in development, there is interest in accurately measuring HD progression and characterising prognostic variables to improve efficiency of clinical trials. Using the large, prospective Enroll-HD cohort, we investigated the relative contribution and ranking of potential prognostic variables in patients with manifest HD. A random forest regression model was trained to predict change of clinical outcomes based on the variables, which were ranked based on their contribution to the prediction. The highest-ranked variables included novel predictors of progression—being accompanied at clinical visit, cognitive impairment, age at diagnosis and tetrabenazine or antipsychotics use—in addition to established predictors, cytosine adenine guanine (CAG) repeat length and CAG-age product. The novel prognostic variables improved the ability of the model to predict clinical outcomes and may be candidates for statistical control in HD clinical studies.